发布求助
文献互助 智能选刊 最新文献

Clinical cancer drugs最新文献

筛选
英文 中文
Halogen directed drug design of Ginsenoside for the treatment of Cancer: A Combined Density Functional and Molecular Docking Study 人参皂苷治疗癌症的卤素定向药物设计:密度功能与分子对接的联合研究
Clinical cancer drugs Pub Date : 2019-01-31 DOI: 10.2174/2212697X06666190131160258
S. Biswas, A. B. R. Khalipha, Md Solayman Hossain, Pranta Ray
{"title":"Halogen directed drug design of Ginsenoside for the treatment of Cancer: A Combined Density Functional and Molecular Docking Study","authors":"S. Biswas, A. B. R. Khalipha, Md Solayman Hossain, Pranta Ray","doi":"10.2174/2212697X06666190131160258","DOIUrl":"https://doi.org/10.2174/2212697X06666190131160258","url":null,"abstract":"","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48498587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Robotic Technologies in Cancer Colon Screening 癌症结肠筛查机器人新技术
Clinical cancer drugs Pub Date : 2019-01-31 DOI: 10.2174/2212697X06666181220130020
Luigi Manfredi and Gianfranco Natale
{"title":"New Robotic Technologies in Cancer Colon Screening","authors":"Luigi Manfredi and Gianfranco Natale","doi":"10.2174/2212697X06666181220130020","DOIUrl":"https://doi.org/10.2174/2212697X06666181220130020","url":null,"abstract":": Colorectal cancer (CRC) is the 3 rd most common cause of cancer death worldwide. Regular screening of the asymptomatic population can drastically reduce the mortality rate. CRC screening includes several proceedings although the gold standard remains optical colonoscopy (OC), which is unpleasant, causes pain and discomfort. New technologies exemplified by capsule endoscopy (CE) constitute alternative painless solutions and despite their limitations, e.g. , passive locomotion and absence of on-board instrumentation, are being increasingly used for CRC screening. Research and development centres are investigating novel advanced robotic technologies for diagnostic and therapeutic use. These include wireless communication, active locomotion, sensors, diagnostic, and therapeutic instruments. This review describes the traditional OC procedure and the existing robotic technologies for CRC.","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X06666181220130020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48115844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients? 癌症患者的内分泌治疗可能与认知障碍有关吗？
Clinical cancer drugs Pub Date : 2019-01-31 DOI: 10.2174/2212697X06666181219095936
Riccardo Presciuttini, R. Danesi, G. Bocci
{"title":"May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?","authors":"Riccardo Presciuttini, R. Danesi, G. Bocci","doi":"10.2174/2212697X06666181219095936","DOIUrl":"https://doi.org/10.2174/2212697X06666181219095936","url":null,"abstract":"","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X06666181219095936","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46857952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Formulation and Evaluation of pH Sensitive Sustained Release Hydrogel of Methotrexate 甲氨蝶呤pH敏感缓释水凝胶的研制与评价
Clinical cancer drugs Pub Date : 2019-01-31 DOI: 10.2174/2212697X06666190102105652
S. Kushwaha, Prashant Kumar, A. Rai
{"title":"Formulation and Evaluation of pH Sensitive Sustained Release Hydrogel of Methotrexate","authors":"S. Kushwaha, Prashant Kumar, A. Rai","doi":"10.2174/2212697X06666190102105652","DOIUrl":"https://doi.org/10.2174/2212697X06666190102105652","url":null,"abstract":"Methods: Chitosan/glyceryl monooleate (C/GMO) solution was prepared in 0.33 M citric acid with gentle stirring. The weighed quantity of Drug and Chitosan in the required concentration was stirred with an appropriate quantity of 0.33 M Citric acid for 3 hours. Further, this solution was cooled to 4 o C. Then, to this cooled Chitosan and Drug solution, the desired amount of Glycerol Monooleate was added dropwise with constant stirring to obtain a clear homogenous system. Moreover, it was filtered by membrane filtration using the cellulose membrane. Finally, the prepared pH sensitive formulations were sterilized by autoclaving.","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X06666190102105652","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43750450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erlotinib in Non-Small Cell Lung Cancer: From a thought to Necessity 厄洛替尼治疗非小细胞肺癌:从想法到必要性
Clinical cancer drugs Pub Date : 2019-01-31 DOI: 10.2174/2212697X06666190102110412
Parijat Pandey and Harish Dureja
{"title":"Erlotinib in Non-Small Cell Lung Cancer: From a thought to Necessity","authors":"Parijat Pandey and Harish Dureja","doi":"10.2174/2212697X06666190102110412","DOIUrl":"https://doi.org/10.2174/2212697X06666190102110412","url":null,"abstract":"","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X06666190102110412","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42199854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Preface 前言
Clinical cancer drugs Pub Date : 2018-11-01 DOI: 10.2174/2212697x0501181101114141
G. Francia
{"title":"Preface","authors":"G. Francia","doi":"10.2174/2212697x0501181101114141","DOIUrl":"https://doi.org/10.2174/2212697x0501181101114141","url":null,"abstract":"","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697x0501181101114141","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47962716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oxaliplatin for Colorectal Cancer Therapy: A Review 奥沙利铂治疗结直肠癌癌症的研究进展
Clinical cancer drugs Pub Date : 2018-05-01 DOI: 10.2174/2212697X05666180905094942
Gaurav Sharma, D. Anghore, R. Khare, R. Rawal
{"title":"Oxaliplatin for Colorectal Cancer Therapy: A Review","authors":"Gaurav Sharma, D. Anghore, R. Khare, R. Rawal","doi":"10.2174/2212697X05666180905094942","DOIUrl":"https://doi.org/10.2174/2212697X05666180905094942","url":null,"abstract":"","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X05666180905094942","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49132325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Meet Our Regional Editor 认识我们的区域编辑
Clinical cancer drugs Pub Date : 2018-05-01 DOI: 10.2174/2212697X0501181101114226
G. Bocci
{"title":"Meet Our Regional Editor","authors":"G. Bocci","doi":"10.2174/2212697X0501181101114226","DOIUrl":"https://doi.org/10.2174/2212697X0501181101114226","url":null,"abstract":"Dr. Bocci is a professor of Pharmacology at the University of Pisa. He obtained the degree of Medicine (1995), the degree of Clinical Pharmacology (1999) and a PhD in Pharmacology (2003) from the University of Pisa. Dr. Bocci was post-doctoral fellow for 3 years at the University of Toronto. Dr. Bocci is PI of projects granted by international associations, foundations and pharmaceutical companies. He is member of ASCO and AACR. He is author of more than 130 scientific papers published on international journals, 11 chapters on books, and 5 patents. He is regional editor of Clinical Cancer Drugs from the foundation of the journal.","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48149556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between C1236T (rs1128503) Variant in ABCB1 Gene and Breast Cancer Recurrence ABCB1基因C1236T (rs1128503)变异与乳腺癌复发的关系
Clinical cancer drugs Pub Date : 2018-05-01 DOI: 10.2174/2212697X05666180716145923
Roby Will Vencatto, F. Marson, C. Martins, L. Bonadia, C. Lima, C. Bertuzzo
{"title":"Association Between C1236T (rs1128503) Variant in ABCB1 Gene and Breast Cancer Recurrence","authors":"Roby Will Vencatto, F. Marson, C. Martins, L. Bonadia, C. Lima, C. Bertuzzo","doi":"10.2174/2212697X05666180716145923","DOIUrl":"https://doi.org/10.2174/2212697X05666180716145923","url":null,"abstract":"","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X05666180716145923","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45149148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Currently Approved Poly (Adenosine Diphosphate-Ribose) Inhibitors in Ovarian Cancer: Current Status and Future Directions 目前批准的卵巢癌多腺苷二磷酸核糖抑制剂:现状和未来方向
Clinical cancer drugs Pub Date : 2018-05-01 DOI: 10.2174/2212697X05666180706161252
Gonzalo H. Giornelli and Pablo Mando
{"title":"Currently Approved Poly (Adenosine Diphosphate-Ribose) Inhibitors in Ovarian Cancer: Current Status and Future Directions","authors":"Gonzalo H. Giornelli and Pablo Mando","doi":"10.2174/2212697X05666180706161252","DOIUrl":"https://doi.org/10.2174/2212697X05666180706161252","url":null,"abstract":"DOI: 10.2174/2212697X05666180706161252 Abstract: Background: Poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors have entered into the clinic rapidly and are becoming a powerful therapeutic tool, especially in the management of BRCA associated ovarian cancers. PARP inhibitors have exploited the homologous recombination deficiency, present in up to 50% of ovarian cancers, through synthetic lethality: A novel therapeutic approach to this disease. Objective: Through an extensive review of PARP inhibitors we evaluated the existing evidence in the clinical trial as monotherapy and combined with chemotherapy in ovarian cancer.","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X05666180706161252","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44136225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信